TIGIT Cancer Research Results

TIGIT, WUCAM, VSTM3, VSIG9, T Cell Immunoreceptor With Ig And ITIM Domains: Click to Expand ⟱
Source:
Type:

TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) — Inhibitory immune-checkpoint receptor expressed primarily on activated T cells, exhausted T cells, regulatory T cells, and natural killer (NK) cells. TIGIT binds mainly to CD155/PVR and also to CD112/NECTIN2, suppressing T-cell and NK-cell activation and cytotoxicity.

Typical modulation in cancer: Frequently ↑ on tumor-infiltrating lymphocytes and generally unfavorable. Increased TIGIT signaling is associated with T-cell exhaustion, reduced NK-cell cytotoxicity, immune evasion, and impaired antitumor immunity. TIGIT blockade is being investigated clinically, often in combination with PD-1/PD-L1 inhibition.

Typical mechanistic relationship: CD155/PVR or CD112/NECTIN2 → TIGIT activation → inhibitory signaling ↑ → T-cell activation ↓, NK-cell cytotoxicity ↓, cytokine production ↓, and tumor immune escape ↑.

Competitive signaling: CD155/PVR can also bind the activating receptor CD226/DNAM-1. TIGIT competes with CD226 for ligand binding and generally shifts signaling toward immune inhibition.
Scientific Papers found: Click to Expand⟱
9246- ISO, IH,    Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cells
- in-vitro, BC, 4T1
TumCP↓, TumCMig↓, Tumccf↓, ROS↑, MMP↓, CD155↓, TIGIT↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCP↓, 1,  

Migration(tgid=13) ⓘ

TumCMig↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD155↓, 1,   TIGIT↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Tumccf↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TIGIT, WUCAM, VSTM3, VSIG9, T Cell Immunoreceptor With Ig And ITIM Domains
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1932  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page